Literature DB >> 16304078

Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.

David A Henry1, Suzanne R Hill, Anthony Harris.   

Abstract

Mesh:

Year:  2005        PMID: 16304078     DOI: 10.1001/jama.294.20.2630

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  23 in total

1.  Common Drug Review recommendations: an evidence base for expectations?

Authors:  Angela Rocchi; Elizabeth Miller; Robert B Hopkins; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

3.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Spiralling Medical Costs: Why Canada Needs NICE Medicine.

Authors:  Norman J Temple
Journal:  Healthc Policy       Date:  2007-11

5.  Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario.

Authors:  R Ramjeesingh; R M Meyer; M Brouwers; B E Chen; C M Booth
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

Review 6.  Successes, challenges and developments in Australian rheumatology.

Authors:  Eric F Morand; Michelle T Leech
Journal:  Nat Rev Rheumatol       Date:  2015-03-10       Impact factor: 20.543

Review 7.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

Review 8.  Measuring health-related quality of life in drug clinical trials: is it given due importance?

Authors:  Ramón San Miguel; Ana María López-González; Eduardo Sanchez-Iriso; Javier Mar; Juan M Cabasés
Journal:  Pharm World Sci       Date:  2007-08-25

Review 9.  Immuno-Oncology Medicines: Policy Implications and Economic Considerations.

Authors:  Georges Adunlin; Stefanie P Ferreri; Jenny Dong; Maisha Kelly Freeman
Journal:  Innov Pharm       Date:  2019-08-08

10.  Funding illness prevention and health promotion in Australia: a way forward.

Authors:  Anthony Harris; Duncan Mortimer
Journal:  Aust New Zealand Health Policy       Date:  2009-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.